Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
Panelists discuss how treatment strategies and sequencing decisions for patients with multiple myeloma who decline transplantation despite eligibility must be carefully tailored, considering both immediate therapeutic goals and potential future treatment options.
Video content above is prompted by the following:
- For patients who may be eligible for transplantation but decline, what is your preferred treatment approach in this population?
- How might a patient’s transplant status impact your sequencing strategy?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
